Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell Therapy

Video

The assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital discussed the session she moderated at the ASH 2022 annual meeting.

“[The session] looked at novel predictors of both response and toxicity to [CAR T-cell] therapies. This is an area with a lot of research going on, we know that these CAR T-cell products can have remarkable impact on making oncologic diseases go away, at least in the short term. But we also know that for some patients, it doesn't work. It doesn't last, and some get really sick. And so, there's a lot of work going into trying to figure out how we can know who that patient is ahead of time, to better guide our therapies and our management.”

A session moderated by Aimee C. Talleur, MD, assistant member of the bone marrow transplant department at St. Jude Children’s Research Hospital at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana, focused on identifying novel predictors of response or toxicity to cellular therapies.

CGTLive spoke with Talleur to learn more about the need for being able to better predict both a patient’s response and toxicity susceptibility to cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, which could allow patients and clinicians to be better informed about therapies on an individual basis. She also discussed unmet needs that remain specifically in assessing therapies in pediatric patients and the challenges that come in that population.

Click here to read more coverage of the ASH 2022 meeting.

REFERENCE
Talleur AC, Phillips CL. Cellular immunotherapies: Novel predictors of response or toxicity to cellular therapies. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, in New Orleans, Lousiana. Session #705.
Related Videos
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
© 2024 MJH Life Sciences

All rights reserved.